Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.32 |
| ▸ | SOD3 | P08294 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19779338 | 1.00 | HCAR2 (0.35) | HCAR2LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21719609 | 1.00 | HCAR2 (0.35) | HCAR2LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL19618178 | 0.94 | HCAR2 (0.33) | HCAR2LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL23583949 | 0.82 | CYP1A2 (0.38) | HCAR2LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21718612 | 0.82 | CYP1A2 (0.38) | HCAR2LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL20049986 | 0.82 | CYP1A2 (0.38) | HCAR2LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21719791 | 0.81 | CNR2 (0.32) | HCAR2LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21719757 | 0.81 | CNR2 (0.32) | HCAR2LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21720041 | 0.81 | CNR2 (0.32) | HCAR2LMNAMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL21719755 | 0.78 | GPR84 (0.36) | HCAR2MAPTCNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098983-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, AKT3, PIK3C2A | HCAR2 3401/4885LMNA 691/4885MAPT 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.